[HTML][HTML] Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative …
B Chun, J Pucilowska, SC Chang, I Kim… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast …
B Chun, J Pucilowska, S Chang, I Kim… - … for Immunotherapy of …, 2022 - europepmc.org
Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
[PDF][PDF] Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative …
B Chun, J Pucilowska, SC Chang, I Kim, B Nikitin… - academia.edu
Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast …
B Chun, J Pucilowska, SC Chang… - J Immunother …, 2022 - digitalcommons.providence.org
BACKGROUND: Chemoimmunotherapy is a standard treatment for triple-negative breast
cancer (TNBC), however, the impacts of different chemotherapies on T-cell populations …
cancer (TNBC), however, the impacts of different chemotherapies on T-cell populations …
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast …
B Chun, J Pucilowska, SC Chang… - Journal for …, 2022 - providence.elsevierpure.com
BackgroundChemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast …
B Chun, J Pucilowska… - Journal for …, 2022 - utsouthwestern.elsevierpure.com
BackgroundChemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
[HTML][HTML] Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative …
B Chun, J Pucilowska, SC Chang, I Kim… - … for ImmunoTherapy of …, 2022 - jitc.bmj.com
Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast …
B Chun, J Pucilowska, SC Chang… - Journal for …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast …
B Chun, J Pucilowska, SC Chang, I Kim… - Journal for …, 2022 - search.proquest.com
Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …